Research programme: DNA helicase inhibitors - Eisbach Bio/University of Texas M. D. Anderson Cancer Center
Alternative Names: Research programme: helicase inhibitors - Eisbach BioLatest Information Update: 10 Nov 2023
At a glance
- Originator Eisbach Bio; University of Texas M. D. Anderson Cancer Center
- Developer Eisbach Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 Nov 2023 Early research in Cancer in Germany (unspecified route) prior to November 2023 (Eisbach Bio pipeline, November 2023)